SEGAL ROBERT-MD 4
4 · DISCOVERY LABORATORIES INC /DE/ · Filed Jan 5, 2006
Insider Transaction Report
Form 4
SEGAL ROBERT-MD
Sr VP, Chief Medical Officer
Transactions
- Award
Common Stock
2006-01-03+4,000→ 8,951 total - Award
Incentive Stock Option (right to buy)
2006-01-03+25,000→ 25,000 totalExercise: $7.01From: 2006-01-03Exp: 2016-01-03→ Common Stock (25,000 underlying) - Award
Common Stock
2005-07-21$6.46/sh+271$1,751→ 4,680 total - Award
Common Stock
2005-10-21$6.45/sh+271$1,748→ 4,951 total
Footnotes (3)
- [F1]Transaction reported on Table I represents Issuer's matching stock contribution pursuant to 401(k) plan.
- [F2]New restricted stock award shall fully vest on the date that Surfaxin for RDS first becomes widely commercially available, as such date is determined by the Company.
- [F3]This employee stock option shall vest 25% on the date of the grant, and the balance shall vest in a series of three successive equal annual installments beginning with the first year anniversary of the grant.